Cargando…

Mast Cells and Dendritic Cells as Cellular Immune Checkpoints in Immunotherapy of Solid Tumors

The immune checkpoint inhibitors have revolutionized cancer immunotherapy. These inhibitors are game changers in many cancers and for many patients, sometimes show unprecedented therapeutic efficacy. However, their therapeutic efficacy is largely limited in many solid tumors where the tumor-controll...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kalkusova, Katerina, Smite, Sindija, Darras, Elea, Taborska, Pavla, Stakheev, Dmitry, Vannucci, Luca, Bartunkova, Jirina, Smrz, Daniel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9569882/ https://www.ncbi.nlm.nih.gov/pubmed/36232398 http://dx.doi.org/10.3390/ijms231911080

Ejemplares similares

LL-37 as a Powerful Molecular Tool for Boosting the Performance of Ex Vivo-Produced Human Dendritic Cells for Cancer Immunotherapy
por: Stakheev, Dmitry, et al.
Publicado: (2022)

Thapsigargin-Stimulated LAD2 Human Mast Cell Line Is a Potent Cellular Adjuvant for the Maturation of Monocyte-Derived Dendritic Cells for Adoptive Cellular Immunotherapy
por: Taborska, Pavla, et al.
Publicado: (2021)

The Role of miR-155 in Antitumor Immunity
por: Kalkusova, Katerina, et al.
Publicado: (2022)

SARS‐CoV‐2 spike glycoprotein‐reactive T cells can be readily expanded from COVID‐19 vaccinated donors
por: Taborska, Pavla, et al.
Publicado: (2021)

CD4(+) T Cells of Prostate Cancer Patients Have Decreased Immune Responses to Antigens Derived From SARS-CoV-2 Spike Glycoprotein
por: Taborska, Pavla, et al.
Publicado: (2021)

The WNT/β-catenin signaling inhibitor XAV939 enhances the elimination of LNCaP and PC-3 prostate cancer cells by prostate cancer patient lymphocytes in vitro
por: Stakheev, Dmitry, et al.
Publicado: (2019)

Acute Conditioning of Antigen-Expanded CD8(+) T Cells via the GSK3β-mTORC Axis Differentially Dictates Their Immediate and Distal Responses after Antigen Rechallenge
por: Taborska, Pavla, et al.
Publicado: (2020)

Effectiveness and Durability of mRNA Vaccine-Induced SARS-CoV-2-Specific Humoral and Cellular Immunity in Severe Asthma Patients on Biological Therapy
por: Podrazil, Michal, et al.
Publicado: (2022)

Novel PD-L1- and collagen-expressing patient-derived cell line of undifferentiated pleomorphic sarcoma (JBT19) as a model for cancer immunotherapy
por: Taborska, Pavla, et al.
Publicado: (2023)

Fas-Fas Ligand Interplay in the Periphery of Salivary Gland Carcinomas as a New Checkpoint Predictor for Disease Severity and Immunotherapy Response
por: Strizova, Zuzana, et al.
Publicado: (2021)

Poly I: C-activated dendritic cells that were generated in CellGro for use in cancer immunotherapy trials
por: Fučíková, Jitka, et al.
Publicado: (2011)

Tumoral and paratumoral NK cells and CD8(+) T cells of esophageal carcinoma patients express high levels of CD47
por: Strizova, Zuzana, et al.
Publicado: (2020)

Induction of Tolerance and Immunity by Dendritic Cells: Mechanisms and Clinical Applications
por: Fucikova, Jitka, et al.
Publicado: (2019)

Phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer
por: Podrazil, Michal, et al.
Publicado: (2015)

The Periphery of Salivary Gland Carcinoma Tumors Reveals a PD-L1/PD-1 Biomarker Niche for the Evaluation of Disease Severity and Tumor—Immune System Interplay
por: Kuchar, Martin, et al.
Publicado: (2021)

The TRAIL in the Treatment of Human Cancer: An Update on Clinical Trials
por: Snajdauf, Martin, et al.
Publicado: (2021)

Early and strong antibody responses to SARS-CoV-2 predict disease severity in COVID-19 patients
por: Plūme, Jānis, et al.
Publicado: (2022)

Novel Insights into the Immunotherapy of Soft Tissue Sarcomas: Do We Need a Change of Perspective?
por: Ozaniak, Andrej, et al.
Publicado: (2021)

Autologous dendritic cell immunotherapy (DCVAC/PCa) added to docetaxel chemotherapy in a Phase III trial (viable) in men with advanced (mCRPC) prostate cancer
por: Beer, Tomasz M, et al.
Publicado: (2015)

Mast Cell Desensitization in Allergen Immunotherapy
por: López-Sanz, Celia, et al.
Publicado: (2022)

Mast Cells and Resistance to Immunotherapy in Cancer
por: Ribatti, Domenico
Publicado: (2023)

Dendritic Cell-Based Immunotherapy for Solid Tumors()()
por: Jung, Nam-Chul, et al.
Publicado: (2018)

On the Other Side: Manipulating the Immune Checkpoint Landscape of Dendritic Cells to Enhance Cancer Immunotherapy
por: Kong, Benjamin Y., et al.
Publicado: (2019)

Advances in Anti-Cancer Immunotherapy: Car-T Cell, Checkpoint Inhibitors, Dendritic Cell Vaccines, and Oncolytic Viruses, and Emerging Cellular and Molecular Targets
por: Alard, Emilie, et al.
Publicado: (2020)

Clinical Outcome of Coronavirus Disease 2019 in Patients with Primary Antibody Deficiencies
por: Milota, Tomas, et al.
Publicado: (2023)

Mast Cells: A New Frontier for Cancer Immunotherapy
por: Lichterman, Jake N., et al.
Publicado: (2021)

Frenemies in the Microenvironment: Harnessing Mast Cells for Cancer Immunotherapy
por: Sulsenti, Roberta, et al.
Publicado: (2023)

Dendritic cells pulsed with tumor cells killed by high hydrostatic pressure induce strong immune responses and display therapeutic effects both in murine TC-1 and TRAMP-C2 tumors when combined with docetaxel chemotherapy
por: MIKYŠKOVÁ, ROMANA, et al.
Publicado: (2015)

Editorial: Dendritic Cell-Based Immunotherapy in Solid and Haematologic Tumors
por: Dolcetti, Riccardo, et al.
Publicado: (2020)

Complex evaluation of human monocyte-derived dendritic cells for cancer immunotherapy
por: Vopenkova, Katerina, et al.
Publicado: (2012)

Dendritic Cells and Their Role in Immunotherapy
por: Gardner, Alycia, et al.
Publicado: (2020)

Tolerogenic IDO(+) Dendritic Cells Are Induced by PD-1-Expressing Mast Cells
por: Rodrigues, Cecilia Pessoa, et al.
Publicado: (2016)

Mast cells acquire MHCII from dendritic cells during skin inflammation
por: Dudeck, Jan, et al.
Publicado: (2017)

Oral Immunotherapy and Basophil and Mast Cell Reactivity in Food Allergy
por: Paranjape, Anuya, et al.
Publicado: (2020)

Human Tumor Targeted Cytotoxic Mast Cells for Cancer Immunotherapy
por: Fereydouni, Mohammad, et al.
Publicado: (2022)

Mast cells and dendritic cells form synapses that facilitate antigen transfer for T cell activation
por: Carroll-Portillo, Amanda, et al.
Publicado: (2015)

The expression profiles of CD47 in the tumor microenvironment of salivary gland cancers: a next step in histology-driven immunotherapy
por: Votava, Michal, et al.
Publicado: (2022)

NK Cell Dysfunction and Checkpoint Immunotherapy
por: Bi, Jiacheng, et al.
Publicado: (2019)

Safety and efficacy of dendritic cell-based immunotherapy DCVAC/OvCa added to first-line chemotherapy (carboplatin plus paclitaxel) for epithelial ovarian cancer: a phase 2, open-label, multicenter, randomized trial
por: Rob, Lukas, et al.
Publicado: (2022)

Requirement of Interaction between Mast Cells and Skin Dendritic Cells to Establish Contact Hypersensitivity
por: Otsuka, Atsushi, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_7p82rsfr8r4a8mtuhe1snclcus